NIAID trial enrolling hospital patients in remdesivir combination therapies

Over the next several months, the National Institute of Allergy and Infectious Diseases expects to enroll up to 1,500 adult COVID-19 hospital patients who require supplemental oxygen in a global clinical trial that aims to determine whether baricitinib or dexamethasone is more effective at preventing mechanical ventilation or death when administered with remdesivir. One group of participants will receive dexamethasone and remdesivir, and another group will receive remdesivir and baricitinib.